Cytoreduction and Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis

A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.

The purpose of this study is to see if there is a difference in survival between two different treatment strategies for colorectal peritoneal surface disease. The control arm administered the currently considered standard treatment which is palliative systemic chemotherapy. The experimental arm received the combination treatment cytoreductive surgery and intraperitoneal chemotherapy. The investigators hypothesis is that the combination treatment will improve the overall survival.

Inclusion Criteria:

• Metastatic disease to the peritoneum from colon or rectum (at least two isolated sites of disease)
• verified primary tumor of adenocarcinoma of the colon or rectum
• Potential resectability as judged by the treating surgeon
• Patient is available for follow-up according to the study protocol
• Signed informed consent

Exclusion Criteria:

• Extraabdominal metastases or liver metastases
• Paraaortic or other inoperable lymph node metastases
• Clear indication for surgery only (such as obstruction, bleeding or peritonitis)
• Prior treatment of either arm in the study
• Clinical or histopathological diagnosis of Peritoneal Pseudomyxoma
• Age > 80
• Contraindications for chemotherapy
• Pregnancy or breastfeeding
• Ongoing infection